Alpha Tau Medical Ltd. (NASDAQ:DRTS) Forecasted to Post Q2 2025 Earnings of ($0.13) Per Share

Alpha Tau Medical Ltd. (NASDAQ:DRTSFree Report) – Equities researchers at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Alpha Tau Medical in a report released on Wednesday, May 22nd. HC Wainwright analyst Y. Chen expects that the company will post earnings per share of ($0.13) for the quarter. HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.51) per share.

Alpha Tau Medical (NASDAQ:DRTSGet Free Report) last released its quarterly earnings results on Monday, May 20th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02.

Alpha Tau Medical Trading Down 2.2 %

Shares of NASDAQ:DRTS opened at $2.65 on Thursday. The business’s 50 day moving average price is $2.72 and its 200-day moving average price is $2.94. Alpha Tau Medical has a 1 year low of $2.15 and a 1 year high of $4.80. The firm has a market capitalization of $184.63 million, a price-to-earnings ratio of -6.46 and a beta of 0.75. The company has a debt-to-equity ratio of 0.07, a current ratio of 11.60 and a quick ratio of 12.07.

Institutional Trading of Alpha Tau Medical

Several large investors have recently added to or reduced their stakes in the stock. Levin Capital Strategies L.P. increased its holdings in shares of Alpha Tau Medical by 2.6% during the 1st quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock worth $999,000 after buying an additional 8,641 shares during the last quarter. USAdvisors Wealth Management LLC acquired a new stake in Alpha Tau Medical during the first quarter worth $30,000. Private Advisor Group LLC purchased a new stake in Alpha Tau Medical in the fourth quarter valued at $176,000. Telemus Capital LLC acquired a new position in shares of Alpha Tau Medical in the 4th quarter valued at $89,000. Finally, Satovsky Asset Management LLC purchased a new position in shares of Alpha Tau Medical during the 4th quarter worth $176,000. 2.65% of the stock is currently owned by hedge funds and other institutional investors.

Alpha Tau Medical Company Profile

(Get Free Report)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.

Featured Articles

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with's FREE daily email newsletter.